Deutsche Bank Analysts Give Novartis (VTX:NOVN) a CHF 85 Price Target

Novartis (VTX:NOVN) has been assigned a CHF 85 price objective by stock analysts at Deutsche Bank in a report issued on Tuesday, May 7th, Borsen Zeitung reports. The firm currently has a “neutral” rating on the stock.

A number of other brokerages also recently issued reports on NOVN. JPMorgan Chase & Co. set a CHF 85 target price on Novartis and gave the stock a “sell” rating in a research note on Tuesday, February 26th. HSBC set a CHF 86 target price on Novartis and gave the stock a “neutral” rating in a research note on Wednesday, February 6th. Barclays set a CHF 75 price target on Novartis and gave the stock a “sell” rating in a report on Friday, February 1st. Credit Suisse Group set a CHF 86 price target on Novartis and gave the stock a “neutral” rating in a report on Thursday, January 31st. Finally, Goldman Sachs Group set a CHF 110 price target on Novartis and gave the stock a “buy” rating in a report on Thursday, January 31st. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. Novartis has an average rating of “Hold” and a consensus price target of CHF 88.88.

Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Further Reading: 52-Week High/Low

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply